uniQure N.V. (QURE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

uniQure N.V. (QURE) closed at USD 20.97 on 2026-10-14, a change of -70 % over the past year, with a market capitalization of USD 1.56B.

uniQure N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

uniQure N.V. key figures

Previous close

USD 20.97 (2026-10-14)

1-year change

-70 %

Market cap

USD 1.56B

Enterprise value

USD 1.3B

P/E ratio (trailing)

-5.29

P/E ratio (forward)

-7.61

EPS (trailing)

-4.26

EPS (forward)

-2.96

PEG ratio

n/a

Price to book

4.82

Revenue growth

11 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.90

Employees

221

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for uniQure N.V. and compare it with other stocks.